Demegen Overview

  • Founded
  • 1992
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 4
  • Investments
  • 1

Demegen General Information

Description

Developer of peptides for the treatment and prevention of infections caused due to multi drug resistant bacteria and fungi. The company develops products for the treatment of dermatological, vaginal, respiratory, ophthalmic and oral diseases with the peptides bind to and kill harmful microorganisms.

Contact Information

Website
Formerly Known As
Demeter BioTechnologies
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Par Advance Technologies
Primary Office
  • 100 Technology Drive
  • Suite 440B
  • Pittsburgh, PA 15219
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Demegen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Demegen‘s full profile, request access.

Request a free trial

Demegen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of peptides for the treatment and prevention of infections caused due to multi drug resistant bacteria and fun
Biotechnology
Pittsburgh, PA
000
000000&0 000

000000 0

usmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exer
0000000000000
Salt Lake City, UT
0000 As of 0000
00000
000000 - 000 00000

00000000

dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui o
0000000000000
Aurora, CO
0 As of 0000
0000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Demegen Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Myriad Genetics Corporation Salt Lake City, UT 0000 00000 000000 - 000 00000
00000000000 Corporation Aurora, CO 0 0000000000
00000000 000000000 Venture Capital-Backed Wuxi, China 00000 00000000000 00000
0000000 0000000000 Venture Capital-Backed Boston, MA 00 000.00 00000000000 000.00
To view Demegen’s complete competitors history, request access »

Demegen Executive Team (1)

Name Title Board Seat Contact Info
Richard Ekstrom Chief Executive Officer
To view Demegen’s complete executive team members history, request access »

Demegen Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Demegen‘s full profile, request access.

Request a free trial

Demegen Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000000 01-Jan-2001 000000000000000000 Other Pharmaceuticals and Biotechnology
To view Demegen’s complete acquisitions history, request access »